Role of Preoperative Biliary Stenting and Preoperative Preparation Before Pancreaticoduodenectomy
Executive Summary
Pancreatic cancer remains a highly lethal malignancy, with surgical resection (specifically pancreaticoduodenectomy) serving as the only potentially curative treatment for the 15–20% of patients who qualify. Given the high morbidity associated with these procedures, preoperative management—specifically the role of Preoperative Biliary Drainage (PBD) and rigorous risk stratification—is critical to improving outcomes.
The use of routine PBD remains controversial. While intended to alleviate symptoms of obstructive jaundice and cholestasis (such as hepatic injury and impaired immune function), clinical trials like the DROP study have indicated that routine PBD may actually increase serious complication rates (74% vs. 39% for surgery alone). Consequently, current guidelines recommend PBD only for specific indications, such as acute cholangitis, intense pruritus, or when surgery is delayed by more than two weeks. When stenting is necessary, self-expanding metallic stents (SEMSs) are preferred over plastic stents due to superior patency and durability.
Comprehensive preoperative preparation involves a multidisciplinary approach focusing on risk assessment using tools like the Revised Goldman Cardiac Risk Index and the ACS-NSQIP Surgical Risk Calculator. Optimization strategies include nutritional support for malnourished patients, pharmacologic thromboprophylaxis for high-risk venous thromboembolism (VTE), and early discharge planning, particularly for patients over age 70 or those with multiple comorbidities.
1. Clinical Context and Survival Outcomes
Pancreatic cancer is characterized by a dismal prognosis. In the United States, an estimated 53,070 new cases were diagnosed in 2017. Approximately 85% of these are adenocarcinomas.
2. Preoperative Biliary Stenting (PBD)
2.1 Historical Development and Purpose
The need for biliary decompression was first described by Allen O. Whipple in 1935. Modern techniques evolved from surgical bypass to percutaneous transhepatic biliary decompression (1974) and eventually endoscopic biliary stenting (1980). The primary physiological goal is to combat the adverse effects of cholestasis, including:
Direct hepatic injury.
Impaired immune, cardiovascular, and renal function.
Relief of jaundice and pruritus.
Facilitating neoadjuvant therapy for locally advanced cases.
2.2 Clinical Controversy and Evidence
The routine application of PBD is debated due to conflicting data regarding its impact on morbidity and mortality.
The DROP Trial (DRainage vs. OPeration): This study found that patients undergoing PBD for 4–6 weeks prior to surgery had significantly higher rates of overall serious complications (74%) compared to those proceeding directly to surgery (39%).
Cochrane Review (2012): Analyzed six trials (520 patients) and concluded there is insufficient evidence to support or refute routine PBD. It specifically noted that PBD did not reduce mortality in patients with obstructive jaundice.
2.3 Indications for Stenting
Because of the risks associated with endoscopic retrograde cholangiopancreatography (ERCP)—including infection, pancreatitis, and bleeding—PBD is reserved for specific clinical scenarios:
3. Stent Selection and Complications
Endoscopic stenting is technically successful in over 90% of cases. The choice of stent must be individualized based on the patient's needs and the expected duration until surgery.
3.1 Plastic vs. Metallic Stents
Plastic Stents: Composed of teflon, polyurethane, or polyethylene. They are inexpensive but prone to occlusion by sludge or bacterial biofilm. Patency ranges from 60 to 200 days.
Metallic Stents (SEMSs): Preferred when PBD is indicated. They offer superior durability and mean patency rates of approximately 278 days. They are available in uncovered, partially covered, and fully covered varieties.
3.2 Complications of Stenting
Occlusion and Migration: Approximately 5% migration for plastic and partially covered SEMSs; 20% for fully covered SEMSs.
Procedure-Related: Pancreatitis, perforation, bleeding, cholecystitis, and cholangitis.
4. Preoperative Risk Stratification
4.1 Cardiovascular and Pulmonary Assessment
Patients must be evaluated for functional status and comorbid conditions.
Functional Status: Poor functional status—defined as the inability to climb two flights of stairs or walk four blocks—increases postoperative risk.
Smoking: Increases risks of pulmonary and wound complications. Smoking cessation is recommended at least one month prior to surgery.
Revised Goldman Cardiac Risk Index (RCRI): Uses six independent predictors to estimate the risk of cardiac death or nonfatal myocardial infarction.
Predictors of Cardiac Risk:
High-risk surgery (e.g., open intraperitoneal procedures).
History of ischemic heart disease.
History of Heart Failure (HF).
History of cerebrovascular disease.
Diabetes mellitus requiring insulin.
Preoperative serum creatinine >2.0 mg/dL.
4.2 Surgical Risk Calculators
ACS NSQIP Surgical Risk Calculator: A decision-support tool using 20 patient risk factors to estimate postoperative complications, death, and length of hospital stay.
Preoperative Nomograms: Specifically developed to predict perioperative mortality following pancreatic resection for malignancy.
5. Comprehensive Patient Preparation
5.1 Optimization Strategies
Nutritional Support: Over one-third of patients lose >10% of body weight before diagnosis. Severely malnourished patients should receive 7–10 days of preoperative parenteral nutritional support.
Thromboprophylaxis: Pancreatic cancer patients are at high risk for VTE. Pharmacologic thromboprophylaxis and intermittent pneumatic compression devices are recommended before anesthesia induction.
Bowel Preparation: While studies (e.g., Lavu et al.) show no significant benefit, many surgeons still employ mechanical or antibiotic bowel preparation.
5.2 Diagnosis and Staging
While imaging is often sufficient for diagnosis, tissue biopsy is mandatory prior to neoadjuvant therapy. Diagnostic laparoscopy is recommended for those with a high likelihood of occult metastatic disease, as 20–33% of patients presumed resectable by imaging are found to be unresectable intraoperatively.
5.3 Discharge Planning
Planning must begin preoperatively. Postoperative complications such as pancreatic fistula, abscesses, and delayed gastric emptying can significantly impede discharge.
Age Factor: Home discharge rates drop from 68.8% to 36.0% for patients over age 70.
Comorbidities: Patients with three or more preoperative comorbidities are significantly more likely to require post-discharge assistance.
